This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Erley, C. M. Articles by Risler, T. Search for Related Content PubMed PubMed Citation Articles by Erley, C. M. Articles by Risler, T.

Hypertension, Vol 21, 810-815, Copyright © 1993 by American Heart Association

ARTICLES

Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs

CM Erley, U Haefele, N Heyne, N Braun and T Risler
University of Tubingen, Department of Nephrology and Hypertension, FRG.

The effects of four different antihypertensive drugs (the Ca(2+)- channel blocker felodipine, the beta-blocker metoprolol, the angiotensin converting enzyme inhibitor ramipril, and the alpha- blocking agent doxazosin) on microalbuminuria and renal hemodynamics were evaluated in a double-blind, crossover study in 17 patients (10 women, seven men, aged 39 +/- 14 years) with mild-to-moderate essential arterial hypertension and microalbuminuria. Patients were studied after a 2-week placebo phase preceded by 2 weeks off all medication and after 12 weeks of treatment with each drug. Between each drug treatment, there was another 14-day placebo washout period. At the end of the study, we performed two additional 2-week placebo periods. After each placebo and treatment period, we measured albumin excretion during a 3- day collecting period. Renal hemodynamics were assessed by clearance techniques (inulin and p-aminohippurate clearance) at the end of the first and last placebo periods and after each treatment period. All drugs reduced mean arterial pressure and microalbuminuria to a similar and statistically significant (p < 0.05) extent (mean arterial pressure: placebo phase, 116 +/- 5 mm Hg; felodipine, 101 +/- 4 mm Hg; metoprolol, 101 +/- 5 mm Hg; ramipril, 101 +/- 4 mm Hg; doxazosin, 102 +/- 5 mm Hg; urinary albumin excretion: placebo phase, 46 +/- 50 mg/day; felodipine, 18 +/- 23 mg/day; metoprolol, 14 +/- 12 mg/day; ramipril, 16 +/- 16 mg/day; doxazosin, 14 +/- 14 mg/day). Mean arterial pressure levels and urinary albumin excretion returned to baseline after the last placebo period (110 +/- 6 mm Hg and 40 +/- 46 mg/day, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				R. M.A. van de Wal, R. T. Gansevoort, P. van der Harst, F. Boomsma, H.W. Thijs Plokker, D. J. van Veldhuisen, P. E. de Jong, W. H. van Gilst, and A. A. Voors Predictors of Angiotensin-Converting Enzyme Inhibitor-Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients Hypertension, November 1, 2006; 48(5): 870 - 876. [Abstract] [Full Text] [PDF]

				J. M. Pascual, E. Rodilla, C. Gonzalez, S. Perez-Hoyos, and J. Redon Long-Term Impact of Systolic Blood Pressure and Glycemia on the Development of Microalbuminuria in Essential Hypertension Hypertension, June 1, 2005; 45(6): 1125 - 1130. [Abstract] [Full Text] [PDF]

				F. W. Asselbergs, G. F.H. Diercks, H. L. Hillege, A. J. van Boven, W. M.T. Janssen, A. A. Voors, D. de Zeeuw, P. E. de Jong, D. J. van Veldhuisen, W. H. van Gilst, et al. Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria Circulation, November 2, 2004; 110(18): 2809 - 2816. [Abstract] [Full Text] [PDF]

				J. Redon, E. Rovira, A. Miralles, R. Julve, and J. M. Pascual Factors Related to the Occurrence of Microalbuminuria During Antihypertensive Treatment in Essential Hypertension Hypertension, March 1, 2002; 39(3): 794 - 798. [Abstract] [Full Text] [PDF]

				A. S. Reddi, V. R. Nimmagadda, A. Lefkowitz, H.-R. Kuo, and J. S. Bollineni Effect of Antihypertensive Therapy on Renal Injury in Type 2 Diabetic Rats With Hypertension Hypertension, August 1, 2000; 36(2): 233 - 238. [Abstract] [Full Text] [PDF]

				K. Matsumoto, R. Morishita, A. Moriguchi, N. Tomita, Y. Yo, T. Nishii, K. Matsumoto, T. Nakamura, J. Higaki, and T. Ogihara Prevention of Renal Damage by Angiotensin II Blockade, Accompanied by Increased Renal Hepatocyte Growth Factor in Experimental Hypertensive Rats Hypertension, August 1, 1999; 34(2): 279 - 284. [Abstract] [Full Text] [PDF]

				P. Clausen, J. S. Jensen, K. Borch-Johnsen, G. Jensen, and B. Feldt-Rasmussen Ambulatory Blood Pressure and Urinary Albumin Excretion in Clinically Healthy Subjects Hypertension, July 1, 1998; 32(1): 71 - 77. [Abstract] [Full Text] [PDF]

				K. Allikmets, T. Parik, R. Teesalu, and K. Allikmets Antihypertensive and Renal Effects of Isradipine in Essential Hypertension: Focus on Renin System Activity Angiology, November 1, 1997; 48(11): 977 - 983. [Abstract] [PDF]

				G. N. Jyothirmayi, I. Alluru, and A. S. Reddi Doxazosin Prevents Proteinuria and Glomerular Loss of Heparan Sulfate in Diabetic Rats Hypertension, May 1, 1996; 27(5): 1108 - 1114. [Abstract] [Full Text]